Dibenzofuranylethylamines as 5-HT<sub>2A/2C</sub> Receptor Agonists

dc.contributor.affiliationUniversidade de Santiago de Compostela. Departamento de Farmacoloxía, Farmacia e Tecnoloxía Farmacéutica
dc.contributor.affiliationUniversidade de Santiago de Compostela. Centro de Investigación en Medicina Molecular e Enfermidades Crónicas (CiMUS)
dc.contributor.authorYempala, Thirumal
dc.contributor.authorBrea Floriani, José Manuel
dc.contributor.authorLoza García, María Isabel
dc.contributor.authorMatthies, Douglas J.
dc.contributor.authorZapata-Torres, Gerald
dc.contributor.authorCassels, Bruce K.
dc.date.accessioned2026-01-29T08:45:53Z
dc.date.available2026-01-29T08:45:53Z
dc.date.issued2020-01-27
dc.description.abstractThe human 5-HT2 receptor subtypes have high sequence identity in their orthosteric ligand-binding domain, and many agonists are poorly selective between the 5-HT2A and 5-HT2C subtypes. Nevertheless, their activation is associated with different pharmacological outcomes. We synthesized five phenethylamine analogs in which the benzene ring is replaced by a bulky dibenzo[b,d]furan moiety and found a couple with >70-fold 5-HT2C selectivity. Molecular docking studies of the most potent compound (5) at both receptor subtypes revealed the likely structural basis of its selectivity. Although in both cases, some crucial interactions are conserved, the change of the Ala2225.46 residue in the 5-HT2C receptor to the larger Ser2425.46 in the 5-HT 2A subtype, which is the only structural difference between the orthosteric binding pockets of both receptors, weakens a π−π stacking interaction between the dibenzofuran moiety and the important Phe6.52 residue and breaks a hydrogen bond between the dibenzofuran oxygen and Ser5.43 , explaining the selectivity of compound 5 for the 5-HT 2C receptor. We believe that this effect of the residue at position 5.46 merits further exploration in the search for selective 5-HT 2C receptor agonists that are of considerable interest in the treatment of schizophrenia
dc.description.peerreviewedSI
dc.identifier.citationACS Omega 2020, 5, 5, 2260–2266
dc.identifier.doi10.1021/acsomega.9b03430
dc.identifier.essn2470-1343
dc.identifier.urihttps://hdl.handle.net/10347/45557
dc.issue.number2
dc.journal.titleACS Omega
dc.language.isoeng
dc.publisherACS
dc.relation.publisherversionhttps://dx.doi.org/10.1021/acsomega.9b03430
dc.rightsCopyright © 2020 American Chemical Society. This is an open access article published under an ACS AuthorChoice License, which permits copying and redistribution of the article or any adaptations for non-commercial purposes.
dc.rights.accessRightsopen access
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectAgonists
dc.subjectAromatic compounds
dc.subjectCrystal structure
dc.subjectNoncovalent interactions
dc.subjectReceptors
dc.titleDibenzofuranylethylamines as 5-HT<sub>2A/2C</sub> Receptor Agonists
dc.typejournal article
dc.type.hasVersionVoR
dspace.entity.typePublication
relation.isAuthorOfPublication67b19be7-64a8-45c8-a6e4-ed48a4410ef8
relation.isAuthorOfPublication7765cb9b-b630-44dc-9477-dd266a62bb3c
relation.isAuthorOfPublication.latestForDiscovery67b19be7-64a8-45c8-a6e4-ed48a4410ef8

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
ao9b03430.pdf
Size:
1.94 MB
Format:
Adobe Portable Document Format